HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 03-25-2004, 04:35 AM   #1
Paul
Guest
 
Posts: n/a
Aventis submitted US and EU regulatory applications for the use of Taxotere(R) in patients with early-stage breast cancer involving axillary lymph nodes.

The applications are based on data from a large Phase III study that found the combination of Taxotere® doxorubicin and cyclophosphamide (TAC) to significantly improve overall survival in women with early-stage breast cancer and reduce their risk of a relapse compared with the standard regimen of 5-fluorouracil doxorubicin and cyclophosphamide (FAC).

The data from the Breast Cancer International Research Group (BCIRG) 001/ TAX 316 study was presented at the San Antonio Breast Cancer Symposium on December 5 2003 and demonstrated that women with node-positive early-stage breast cancer who received a Taxotere®-based chemotherapy regimen after surgery experienced a 30 percent reduction in the risk of death at a 55-month follow-up and a 28 percent reduction in the chance of their cancer returning as compared to women treated with a commonly used standard (post-surgery) adjuvant regimen.

A similar benefit for TAC over FAC was observed regardless of nodal hormone-receptor or HER-2/neu status.


  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 01:15 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter